Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03049254 · ClinicalTrials.gov registry record
Mayo AVC Registry and Biobank
A clinical trial of Cardiovascular Diseases and Heart Diseases, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 2
- Study locations
NCT03049254 is a study of Cardiovascular Diseases and Heart Diseases that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 1,000 participants, below the 26,971-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT03049254, a study of Cardiovascular Diseases and Heart Diseases, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 2
- Study locations
Study Summary
Arrhythmogenic ventricular cardiomyopathy (AVC) is a genetic condition which affects the heart and can lead to heart failure and rhythm problems, of which, sudden cardiac arrest or death is the most tragic and dangerous. Diagnosis and screening of blood-relatives is very difficult as the disease process can be subtle, but sufficient enough, so that the first event is sudden death. The Mayo Clinic AVC Registry is a collaboration between Mayo Clinic, Rochester, USA and Papworth Hospital, Cambridge University Hospitals, Cambridge, UK. The investigators aim to enroll patients with a history of AVC or sudden cardiac death which may be due to AVC, from the US and UK. Family members who are blood-relatives will also be invited, including those who do not have the condition. Data collected include symptoms, ECG, echocardiographic, MRI, Holter, loop recorder, biopsies, exercise stress testing, blood, buccal and saliva samples. Objectives of the study: 1. Discover new genes or altered genes (variants) which cause AVC 2. Identify biomarkers which predict (2a) disease onset, (2b) disease progression, (2c) and the likelihood of arrhythmia (ventricular, supra-ventricular and atrial fibrillation) 3. Correlate genotype with phenotype in confirmed cases of AVC followed longitudinally using clinical, electrocardiographic and imaging data. 4. Characterize desmosomal changes in buccal mucosal cells with genotype and validate with gold-standard endomyocardial biopsies
Conditions Studied
Study Locations (2)
Minnesota
- Mayo Clinic - Rochester
Cambridge
- Royal Papworth Hospital NHS Foundation Trust - Papworth Everard
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2018-02-09 |
| Est. Completion | 2026-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03049254
The ClinicalTrials.gov registry entry for NCT03049254 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 26,971-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (96% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 0 interventions.
NCT03049254 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Minnesota, Cambridge.
Frequently Asked Questions
What is clinical trial NCT03049254 about?
NCT03049254 is a clinical study titled "Mayo AVC Registry and Biobank". Arrhythmogenic ventricular cardiomyopathy (AVC) is a genetic condition which affects the heart and can lead to heart failure and rhythm problems, of which, sudden cardiac arrest or death is the most tragic and dangerous. Diagnosis and screening of blood-relatives is very difficult as the disease pro...
What is the current status of trial NCT03049254?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2018-02-09. Estimated completion is 2026-03.
What conditions does trial NCT03049254 study?
This clinical trial studies the following conditions: Cardiovascular Diseases, Heart Diseases, Cardiomyopathies, Sudden Cardiac Death, Sudden Cardiac Arrest.
Who is sponsoring clinical trial NCT03049254?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03049254 being conducted?
This trial has 2 study locations across Minnesota, Cambridge. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes
RECRUITING · Phase 1
-
The Influence of Chardonnay Marc Intake on Gut and Cardiometabolic Health
RECRUITING · NA
-
TRANSCRIBE (Transcriptomic Analysis of Left Ventricular Gene Expression)
RECRUITING
-
Identifying Strategies to Reduce Cardiovascular Risk Among Mothers of Young Children
RECRUITING · NA
-
Insomnia Treatment and Cardiometabolic Health in Older Adults With Posttraumatic Stress Disorder
RECRUITING · NA
-
Deep Brain Stimulation Motor Ventral Thalamus (VOP/VIM) for Restoration of Speech and Upper-limb Function in People With Subcortical Stroke
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.